Profiles

Nuri Guven

UTAS Home Associate Professor Nuri Güven

Nuri Güven

Associate Professor of Pharmaceutical Science, Graduate Research Coordinator (Pharmacy)

Room 2032, Chemistry Building, Sandy Bay Campus

+61 3 6226 1715 (phone)

+61 3 6226 2870 (fax)

Nuri.Guven@utas.edu.au

Assoc Prof Gueven is a biochemist with many years experience in pre-clinical, drug-related research using cell-free, cell culture and animal models of human disease. He has worked on cancer and neurodegenerative disorders and has recently turned his interest to mitochondrial dysfunction, which is inherent to a large number of major disorders ranging from cancer to glaucoma. He is testing known compounds, novel extracts but also collaborates with different Australian chemists to develop and test novel drug candidates. His interest lies not only in scientific discovery but also in research that eventually can find its way to patients. Therefore his current research is mainly funded by patient charities as well as commercial sources.

Career summary

Qualifications

  • PhD, University of Konstanz and University of Tübingen, Germany. 1998
  • Masters, University of Konstanz, Germany. 2003

Languages (other than English)

German

Biography

Assoc Prof Gueven joined UTAS in April 2012, where he acted as Deputy Head (School of Pharmacy) and then Associate Deputy Head (School of Medicine, Division of Pharmacy). Previously he directed the pre-clinical research department at Santhera Pharmaceuticals (Liestal, Switzerland, 2008-2012), where he led several drug discovery projects around novel treatments for neuromuscular disorders and in the field of cancer cachexia. From 2001-2008 he was Senior Research Officer at the Queensland Institute of Medical Research (QIMR, Brisbane, Australia), in the DNA damage and repair field, where he specialized in recessive ataxia syndromes, p53, oxidative stress-induced malignancy and animal models. During this time he was chief investigator on 2 NHMRC and 2 Queensland Cancer Fund applications and attracted US funding for his pharmaceutical work in a cancer mouse model as CIA. He worked on an industry-project at the University of Tübingen (Department of Radiationoncology, Germany 1999-2002) to identify the active component of a radioprotective drug. His PhD was awarded in 1998 from the University of Konstanz (Germany) in the area of drug discovery in radiation-oncology.

Research Themes

Nuri's work aligns with the University Theme: 'Better Health'. His core expertise is pre-clinical drug discovery in the area of mitochondrial and metabolic disorders, inflammatory bowel disease as well as cancer. His research spans several disease areas from cancer to neurodegeneration and metabolism.

http://www.utas.edu.au/health/research/groups/drug-discovery-group

Memberships

Professional practice

  • NIH DNA Repair Special Interest Group
  • Associate Investigator of the Australian Research Council (ARC) Centre of Excellence for Free Radical Chemistry and Biotechnology
  • Member of the scientific research advisory committee of the Royal Hobart Hospital Research Foundations (RHHRF) and the Erica Bell Foundation
  • Editorial Board Member: PLOS ONE and J Pharmaceutics & Pharmacology

Administrative expertise

Nuri has previously managed multiple drug discovery projects in academic and commercial settings. In these roles he was responsible for line management of multidisciplinary teams (i.e. screening, PK/PD, ADME, cell biology, in vivo models, molecular biology, exploratory, in and out-licencing). In addition he generated documents and presentations for regulatory bodies (EMA/FDA) incl. the participation in interviews and membership on a drug safety committee. Currently he manages several research projects around drug discovery and toxicity for multiple indications. He also established lab infrastructure from scratch in several academic and commercial institutions (layout, equipment acquisition, lab maintenance, SOP generation, budget control) and has a keen interest and experience to protect scientific discoveries by patent applications.

Nuri has held the following administrative positions:

  • Acting Deputy Head of School (Pharmacy, 2012-2013)
  • Acting Deputy Associate Head (Division of Pharmacy, since 2014)
  • Member of the Faculty of Health Sciences Research Committee (2012-2013)
  • School of Medicine Research Committee (since 2014)
  • UTAS Medical Science Precinct (includes the Menzies Institute for Medical Research) Lab Management Team
  • Established and manages the Pharmacy division's cell culture facility

Teaching

Drug discovery and development, toxicology, pre-clinical research, food-supplements, how to give a presentation

Teaching responsibility

Nuri is involved in the organisation and lectures in a number of units within the School of Medicine:

Research Appointments

  • Scientific consultant to Santhera Pharmaceuticals (2012 - present)
  • Scientific advisory committee Erica Bell Foundation
  • Academic Editor: PLOS ONE
  • Academic Editor: J Pharmaceutics & Pharmacology
  • Additional recent review activity for: NHMRC, Australia; ORIA, Australia; AFM, France, Medical Research Charities Group (MRCG), Ireland; Health Research Board (HRB), Ireland; Action Research, UK

View more on Dr Nuri Guven in WARP

Expertise

Assoc Prof Gueven is a biomedical scientist with an international reputation for drug discovery and development in disorders associated with oxidative stress, energy impairment and malignancies. His current interests lie in drug discovery in the areas of ulcerative colitis, colorectal cancer and metabolic disorders. The collective impact of his contribution is highlighted by numerous worldwide collaborations with clinicians and researchers, invitations to speak at international meetings, invited reviews, patents as well as editorial and refereeing work. He gave the keynote lecture at the Muscular Dystrophy Association of New Zealand (MDA) and Australasian Neuromuscular Network (ANN) Conference 2015 and was also the invited speaker at a specialized Workshop on CoQ10 deficiency disorders and therapy (Naarden, Netherlands 2010). Nuri has also presented his work at more general conferences such as ComBio. The relevance of his applied research to the health of patients is demonstrated by two patent disclosures in 2012, and a novel submitted patent application in 2014 in the field of personalized medicine (undisclosed). He has published in prestigious journals (J Cell Biol, Hum Mol Gen, Cell Death Diff). His work is widely cited (a total of more than 1600 citations) with an average of more than 30 citations/paper and more than 450 citations for the most highly cited paper.

Awards

  • Kevin Cahill Award (2015) for the most interesting or innovative research in the field of Vision Sciences

Collaboration

Assoc Prof Gueven is collaborating with scientists and clinicians worldwide. He has numerous active collaborations in the areas of mitochondrial and neuromuscular disorders and is involved in clinical research around a novel treatment for Duchenne Muscular Dystrophy at the Children's Hospital in Basel (Switzerland). He is also collaborating within the University of Tasmania with Dr. Patel (School of Medicine) and Dr. Eri (School of Health Sciences) on the activity of polysaccharides in inflammatory bowel diseases, with Assoc Prof Foa and Dr. Gasperini (School of Medicine) on drug toxicity measurement in zebrafish, with Dr. Smith (School of Chemistry) on the development of novel short chain quinones for the treatment of mitochondrial dysfunction, with Dr. Hewitt and Dr. Cook (School of Medicine) on the use of iPS derived GRC cells in drug screening approaches, just to name a few. In addition, he also collaborates with commercial entities such as Marinova Pty (Cambridge, TAS, Australia) to evaluate their products in various pre-clinical models of disease.

Current projects

  • Optic neuropathy due to mitochondrial dysfunction in D. rerio (zebrafish) (current)
  • Characterization of DNA damage response of anti-trypanosome compounds (current)
  • Development of short chain quinones for the treatment of mitochondrial disorders (current)
  • Identification of drugs that affect mitochondrial function (current)
  • Fucoidan for the treatment of inflammatory bowel disease (current)
  • Small molecular weight heparins (SMWH) as anti-inflammatory agents (current)

Research Fields

  • Pharmaceutical Sciences (111504)
  • Signal Transduction (060111)
  • Pharmacology and Pharmaceutical Sciences (111599)
  • Basic Pharmacology (111501)
  • Clinical Pharmacology and Therapeutics (111502)
  • Ophthalmology (111301)
  • Neurology and Neuromuscular Diseases (110904)
  • Biologically Active Molecules (030401)
  • Biochemistry and Cell Biology (060199)
  • Clinical Sciences (110399)
  • Medical Biochemistry and Metabolomics (110199)
  • Separation Science (030108)
  • Medicinal and Biomolecular Chemistry (030499)
  • Cell Development, Proliferation and Death (060103)
  • Proteins and Peptides (030406)
  • Central Nervous System (110903)
  • Analytical Biochemistry (060101)
  • Enzymes (060107)
  • Medical Biochemistry: Proteins and Peptides (incl. Medical Proteomics) (110106)
  • Metabolic Medicine (110107)
  • Gene and Molecular Therapy (100401)
  • Motor Control (110603)
  • Animal Cell and Molecular Biology (060802)
  • Analytical Chemistry (030199)
  • Medical and Health Sciences (119999)
  • Biological Psychology (Neuropsychology, Psychopharmacology, Physiological Psychology) (170101)
  • Peripheral Nervous System (110905)
  • Animal Physiology - Systems (060603)
  • Cellular Nervous System (110902)
  • Autonomic Nervous System (110901)
  • Traditional Chinese Medicine and Treatments (110404)
  • Optometry and Ophthalmology (111399)
  • Optical Technology (111302)
  • Pharmacogenomics (111505)
  • Cell Physiology (111601)
  • Animal Physiology - Cell (060602)
  • Epigenetics (incl. Genome Methylation and Epigenomics) (060404)
  • Cell Metabolism (060104)
  • Cell Neurochemistry (060105)

Research Impact

  • Expanding Knowledge in the Biological Sciences (970106)
  • Expanding Knowledge in the Medical and Health Sciences (970111)
  • Health (929999)
  • Digestive System Disorders (920105)
  • Neurodegenerative Disorders Related to Ageing (920112)
  • Hearing, Vision, Speech and Their Disorders (920107)
  • Nervous System and Disorders (920111)
  • Public Health (excl. Specific Population Health) (920499)
  • Cancer and Related Disorders (920102)
  • Expanding Knowledge in the Chemical Sciences (970103)
  • Human Pharmaceutical Products (860899)
  • Human Pharmaceutical Treatments (e.g. Antibiotics) (860803)
  • Respiratory System and Diseases (incl. Asthma) (920115)
  • Immune System and Allergy (920108)
  • Behaviour and Health (920401)
  • Clinical Health (Organs, Diseases and Abnormal Conditions) (920199)
  • Diabetes (920104)
  • Cardiovascular System and Diseases (920103)
  • Aboriginal and Torres Strait Islander Health - Determinants of Health (920301)

Publications

Assoc Prof Guven is widely published with about 50% of publications as first or last author and 3 invited reviews. On average Nuri has published 4.4 papers per year over the last 5 years (excluding patents). Nuri's publications are highly cited (>2000) with a H-factor of 20 and the highest cited paper receiving more than 450 citations. Nuri delivered a seminal paper on the activation of the tumour suppressor p53 in Cell Death and Differentiation and was author on the first paper describing molecular activity of short chain quinones that make them useful to treat mitochondrial disease. Nuri is on two international patents disclosed in 2012 from his work in the pharmaceutical industry, which are now part of the essential IP portfolio of the company. One Australian provisional patent application (2014904633 submitted in 2014) with ongoing licence negotiations.

Total publications

57

Journal Article

(42 outputs)
YearCitationAltmetrics
2016Alhusban A, Breadmore MC, Gueven N, Guijt RM, 'Capillary electrophoresis for automated on-line monitoring of suspension cultures: Correlating cell density, nutrients and metabolites in near real-time', Analytica Chimica Acta: International Journal Devoted to All Branches of Analytical Chemistry ISSN 0003-2670 (2016) [Refereed Article]

DOI: 10.1016/j.aca.2016.03.034 [eCite] [Details]

Co-authors: Breadmore MC; Guijt RM

Tweet

2016Chhetri J, Gueven N, 'Targeting mitochondrial function to protect against vision loss', Expert Opinion on Emerging Therapeutic Targets pp. 1-16. ISSN 1472-8222 (2016) [Refereed Article]

[eCite] [Details]

Co-authors: Chhetri J

2016Hafner P, Bonati U, Erne B, Schmid M, Rubino D, et al., 'Improved Muscle Function in Duchenne Muscular Dystrophy through L-Arginine and Metformin: An Investigator-Initiated, OpenLabel, Single-Center, Proof-Of-Concept-Study', PloS one, 11, (1) Article e0147634. ISSN 1932-6203 (2016) [Refereed Article]

DOI: 10.1371/journal.pone.0147634 [eCite] [Details]

Tweet

2016Gueven N, 'Idebenone for Leber's hereditary optic neuropathy', Drugs of today, 52, (3) pp. 173-81. ISSN 1699-3993 (2016) [Refereed Article]

DOI: 10.1358/dot.2016.52.3.2463564 [eCite] [Details]

Tweet

2015Kijas AW, Lim YC, Bolderson E, Cerosaletti K, Gatei M, et al., 'ATM-dependent phosphorylation of MRE11 controls extent of resection during homology directed repair by signalling through Exonuclease 1', Nucleic Acids Research, 43, (17) pp. 8352-8367. ISSN 0305-1048 (2015) [Refereed Article]

DOI: 10.1093/nar/gkv754 [eCite] [Details]

Citations: Web of Science - 2

Tweet

2015Wanandy T, Guven N, Davies NW, Brown SGA, Wiese MD, 'Pilosulins: A review of the structure and mode of action of venom peptides from an Australian ant Myrmecia pilosula', Toxicon, 98 pp. 54-61. ISSN 0041-0101 (2015) [Refereed Article]

DOI: 10.1016/j.toxicon.2015.02.013 [eCite] [Details]

Citations: Scopus - 5

Co-authors: Wanandy T; Davies NW

Tweet

2015Lean QY, Gueven N, Eri RD, Bhatia R, Sohal SS, et al., 'Heparins in ulcerative colitis: proposed and potential reasons for inconsistent clinical outcomes', Expert Review of Clinical Pharmacology, 8, (6) pp. 795-811. ISSN 1751-2433 (2015) [Refereed Article]

DOI: 10.1586/17512433.2015.1082425 [eCite] [Details]

Co-authors: Lean QY; Eri RD; Sohal SS; Stewart N; Peterson GM; Patel RP

Tweet

2015Shastri MD, Stewart N, Eapen M, Peterson GM, Zaidi STR, et al., 'Opposing effects of low molecular weight heparins on the release of inflammatory cytokines from peripheral blood mononuclear cells of asthmatics', PLoS One, 10, (3) Article e0118798. ISSN 1932-6203 (2015) [Refereed Article]

DOI: 10.1371/journal.pone.0118798 [eCite] [Details]

Citations: Scopus - 3Web of Science - 3

Co-authors: Shastri MD; Stewart N; Eapen M; Peterson GM; Zaidi STR; Sohal SS; Patel RP

Tweet

2015Shastri MD, Stewart N, Horne J, Peterson GM, Gueven N, et al., 'In-vitro suppression of IL-6 and IL-8 release from human pulmonary epithelial cells by non-anticoagulant fraction of enoxaparin', PLoS One, 10, (5) Article e0126763. ISSN 1932-6203 (2015) [Refereed Article]

DOI: 10.1371/journal.pone.0126763 [eCite] [Details]

Co-authors: Shastri MD; Stewart N; Horne J; Peterson GM; Sohal SS; Patel RP

Tweet

2015Shastri MD, Stewart N, Horne J, Zaidi STR, Sohal SS, et al., 'Non-anticoagulant fractions of enoxaparin suppress inflammatory cytokine release from peripheral blood mononuclear cells of allergic asthmatic individuals', PLoS One, 10, (6) Article e0128803. ISSN 1932-6203 (2015) [Refereed Article]

DOI: 10.1371/journal.pone.0128803 [eCite] [Details]

Citations: Scopus - 2Web of Science - 2

Co-authors: Shastri MD; Stewart N; Horne J; Zaidi STR; Sohal SS; Peterson GM; Korner H; Patel RP

Tweet

2015Buyse GM, Gueven N, McDonald CM, 'Idebenone as a novel therapeutic approach for Duchenne Muscular Dystrophy', European Neurological Review, 10, (2) pp. 189-94. ISSN 1758-3837 (2015) [Refereed Article]

DOI: 10.17925/ENR.2015.10.02.189 [eCite] [Details]

Tweet

2015Yin X, Guven N, Dietis N, 'Opioids in depression: not quite there yet', UK Journal of Pharmaceutical and Biosciences, 3, (1) pp. 12-17. ISSN 2347-9442 (2015) [Refereed Article]

[eCite] [Details]

Co-authors: Yin X; Dietis N

2015Lean QY, Eri RD, Fitton JH, Patel RP, Gueven N, 'Fucoidan extracts ameliorate acute colitis', PLoS One, 10, (6) Article e0128453. ISSN 1932-6203 (2015) [Refereed Article]

DOI: 10.1371/journal.pone.0128453 [eCite] [Details]

Citations: Scopus - 7Web of Science - 4

Co-authors: Lean QY; Eri RD; Patel RP

Tweet

2014Chhetri J, Jacobson G, Gueven N, 'Zebrafish - on the move towards ophthalmological research', Eye, 28 pp. 367-380. ISSN 0950-222X (2014) [Refereed Article]

DOI: 10.1038/eye.2014.19 [eCite] [Details]

Citations: Scopus - 14

Co-authors: Chhetri J; Jacobson G

Tweet

2014Lean QY, Patel RP, Stewart N, Sohal SS, Guven N, 'Identification of pro-and anti-proliferative oligosaccharides of heparins', Integrative Biology, 6, (1) pp. 90 - 99. ISSN 0974-2816 (2014) [Refereed Article]

DOI: 10.1039/c3ib40206a [eCite] [Details]

Citations: Scopus - 2Web of Science - 1

Co-authors: Lean QY; Patel RP; Stewart N; Sohal SS

Tweet

2014Paul A, Guven N, Dietis N, 'Opioid receptor-dependent modulation of insulin-release in pancreatic beta-cells', UK Journal of Pharmaceutical and Biosciences, 2, (6) pp. 22-31. ISSN 2347-9442 (2014) [Refereed Article]

[eCite] [Details]

Co-authors: Dietis N

2014Alhusban AA, Gaudry AJ, Breadmore MC, Gueven N, Guijt RM, 'On-line sequential injection-capillary electrophoresis for near-real-time monitoring of extracellular lactate in cell culture flasks', Journal of Chromatography A, 1323 pp. 157-162. ISSN 0021-9673 (2014) [Refereed Article]

DOI: 10.1016/j.chroma.2013.11.006 [eCite] [Details]

Citations: Scopus - 9

Co-authors: Breadmore MC; Guijt RM

Tweet

2013Shabala L, Walker EJ, Eklund A, Randall-Demllo S, Shabala S, et al., 'Exposure of colonic epithelial cells to oxidative and endoplasmic reticulum stress causes rapid potassium efflux and calcium influx', Cell Biochemistry and Function, 31, (7) pp. 603-611. ISSN 1099-0844 (2013) [Refereed Article]

DOI: 10.1002/cbf.2946 [eCite] [Details]

Citations: Scopus - 5Web of Science - 5

Co-authors: Shabala L; Walker EJ; Randall-Demllo S; Shabala S; Cook AL; Eri RD

Tweet

2012Erb M, Hoffmann-Enger B, Deppe H, Soedberdt M, Haefeli RH, et al., 'Features of idebenone and related short-chain quinones that rescue ATP levels under conditions of impaired mitochondrial complex I', PLoS One, 7, (4) Article e36153. ISSN 1932-6203 (2012) [Refereed Article]

DOI: 10.1371/journal.pone.0036153 [eCite] [Details]

Citations: Scopus - 21Web of Science - 17

Tweet

2012Heitz FD, Erb M, Anklin C, Robay D, Pernet V, et al., 'Idebenone protects against retinal damage and loss of vision in a mouse model of Leber's hereditary optic neuropathy', PLoS One, 7, (9) Article e45182. ISSN 1932-6203 (2012) [Refereed Article]

DOI: 10.1371/journal.pone.0045182 [eCite] [Details]

Citations: Scopus - 24Web of Science - 23

Tweet

2012Murad NAA, Cullen JK, McKenzie M, Ryan MT, Thorburn D, et al., 'Mitochondrial dysfunction in a novel form of autosomal recessive ataxia', Mitochondrion, 13, (3) pp. 235-245. ISSN 1872-8278 (2012) [Refereed Article]

DOI: 10.1016/j.mito.2012.11.006 [eCite] [Details]

Citations: Scopus - 3Web of Science - 4

Tweet

2011Brown JA, Roberts TL, Richards R, Woods R, Birrell G, et al., 'A Novel Role for hSMG-1 in Stress Granule Formation', Molecular and Cellular Biology, 31, (2) pp. 4417 - 4429. ISSN 0270-7306 (2011) [Refereed Article]

DOI: 10.1128/MCB.05987-11 [eCite] [Details]

Citations: Scopus - 10Web of Science - 12

Tweet

2011Dallmann R, Weyermann P, Anklin C, Boroff M, Bray-French K, et al., 'The orally active melanocortin-4 receptor antagonist BL-6020/979: a promising candidate for the treatment of cancer cachexia', Journal of Cachexia, Sarcopenia and Muscle, 2, (3) pp. 163-174. ISSN 2190-5991 (2011) [Refereed Article]

DOI: 10.1007/s13539-011-0039-1 [eCite] [Details]

Citations: Scopus - 15Web of Science - 14

Tweet

2011Gatei M, Jakob B, Chen P, Kijas AW, Becherel OJ, et al., 'ATM-Dependent Phosphorylation of RAD50 regulates DNA repair and cell cycle control', Journal of Biological Chemistry, 286, (36) pp. 31542-31556. ISSN 1083-351X (2011) [Refereed Article]

DOI: 10.1074/jbc.M111.258152 [eCite] [Details]

Citations: Scopus - 21Web of Science - 21

Tweet

2011Haefeli RH, Erb M, Gemperli AC, Robay D, Courdier Fruh I, et al., 'NQO1-Dependent Redox Cycling of Idebenone: effects on cellular Redox potential and energy levels', PLoS One, 6, (3) Article e17963. ISSN 1932-6203 (2011) [Refereed Article]

DOI: 10.1371/journal.pone.0017963 [eCite] [Details]

Citations: Scopus - 57Web of Science - 50

Tweet

2010Craig AL, Holcakova J, Finlan LE, Nekulova M, Hrstka R, et al., 'DeltaNp63 transcriptionally regulates ATM to control p53 Serine-15 phosphorylation', Molecular Cancer, 9, (195) pp. 1-13. ISSN 1476-4598 (2010) [Refereed Article]

DOI: 10.1186/1476-4598-9-195 [eCite] [Details]

Citations: Scopus - 19Web of Science - 19

Tweet

2010Morrow BJ, Keddie DJ, Gueven N, Lavin MF, Bottle SE, 'A novel profluorescent nitroxide as a sensitive probe for the cellular redox environment', Free Radical Biology & Medicine, 49, (1) pp. 67-76. ISSN 1873-4596 (2010) [Refereed Article]

DOI: 10.1016/j.freeradbiomed.2010.03.019 [eCite] [Details]

Citations: Scopus - 30Web of Science - 25

Tweet

2009Becherel OJ, Jakob B, Cherry AL, Guven N, Fusser M, et al., 'CK2 phosphorylation-dependent interaction between aprataxin and MDC1 in the DNA damage response', Nucleic Acids Research pp. 1-15. ISSN 1362-4962 (2009) [Refereed Article]

DOI: 10.1093/nar/gkp1149 [eCite] [Details]

Citations: Scopus - 23

Tweet

2007Gueven N, Becherel OJ, Howe O, Chen P, Haince J-F, et al., 'A novel form of ataxia oculomotor apraxia characterized by oxidative stress and apoptosis resistance', Cell Death and Differentiation, 14, (6) pp. 1149-1161. ISSN 1350-9047 (2007) [Refereed Article]

DOI: 10.1038/sj.cdd.4402116 [eCite] [Details]

Citations: Scopus - 11Web of Science - 10

Tweet

2007Gueven N, Chen P, Nakamura J, Becherel OJ, Kijas AW, et al., 'A subgroup of spinocerebellar ataxias defective in DNA damage responses', Neuroscience: An International Journal, 145, (4) pp. 1418-1425. ISSN 0306-4522 (2007) [Refereed Article]

DOI: 10.1016/j.neuroscience.2006.12.010 [eCite] [Details]

Citations: Scopus - 40Web of Science - 37

Tweet

2007Suraweera A, Becherel OJ, Chen P, Rundle N, Woods R, et al., 'Senataxin, defective in ataxia oculomotor apraxia type 2, is involved in the defense against oxidative DNA damage', The Journal of Cell Biology, 177, (6) pp. 969-979. ISSN 1540-8140 (2007) [Refereed Article]

DOI: 10.1083/jcb.200701042 [eCite] [Details]

Citations: Scopus - 97Web of Science - 97

Tweet

2006Gueven N, Luff J, Peng C, Hosokawa K, Bottle SE, et al., 'Dramatic extension of tumor latency and correction of neurobehavioral phenotype in Atm-mutant mice with a nitroxide antioxidant', Free Radical Biology and Medicine, 41, (6) pp. 992-1000. ISSN 0891-5849 (2006) [Refereed Article]

DOI: 10.1016/j.freeradbiomed.2006.06.018 [eCite] [Details]

Citations: Scopus - 41Web of Science - 37

Tweet

2006Lavin MF, Guven N, 'The complexity of p53 stabilization and activation', Cell Death and Differentiation, 13, (6) pp. 941-950. ISSN 1350-9047 (2006) [Refereed Article]

DOI: 10.1038/sj.cdd.4401925 [eCite] [Details]

Citations: Scopus - 401Web of Science - 385

Tweet

2005Truman J-P, Gueven N, Lavin M, Leibel S, Kolesnick R, et al., 'Down-regulation of ATM protein sensitizes human prostate cancer cells to radiation-induced apoptosis', Journal of Biological Chemistry, 280, (24) pp. 23262-23272. ISSN 0021-9258 (2005) [Refereed Article]

DOI: 10.1074/jbc.M503701200 [eCite] [Details]

Citations: Scopus - 43Web of Science - 42

Tweet

2004Gueven N, Becherel OJ, Kijas AW, Chen P, Howe O, et al., 'Aprataxin, a novel protein that protects against genotoxic stress', Human Molecular Genetics, 13, (10) pp. 1081-1093. ISSN 0964-6906 (2004) [Refereed Article]

DOI: 10.1093/hmg/ddh122 [eCite] [Details]

Citations: Scopus - 115Web of Science - 107

Tweet

2004Lavin MF, Scott SP, Kozlov S, Gueven N, 'Analyzing the regulation and function of ATM', Methods in Molecular Biology, 281 pp. 163-178. ISSN 1064-3745 (2004) [Refereed Article]

[eCite] [Details]

2003Glover D, Little JB, Lavin MF, Gueven N, 'Low dose ionizing radiation-induced activation of connexin 43 expression', International Journal of Radiation Biology, 79, (12) pp. 955-964. ISSN 0955-3002 (2003) [Refereed Article]

DOI: 10.1080/09553000310001632895 [eCite] [Details]

Citations: Scopus - 17Web of Science - 16

Tweet

2003Gueven N, Keating K, Fukao T, Loeffler H, Kondo N, et al., 'Site-directed mutagenesis of the ATM promoter: Consequences for response to proliferation and ionizing radiation', Genes, Chromosomes and Cancer, 38, (2) pp. 157-167. ISSN 1045-2257 (2003) [Refereed Article]

DOI: 10.1002/gcc.10261 [eCite] [Details]

Citations: Scopus - 25Web of Science - 25

Tweet

2003Kozlov S, Gueven N, Keating K, Ramsay J, Lavin MF, 'ATP activates ataxia-telangiectasia mutated (ATM) in vitro. Importance of autophosphorylation', Journal of Biological Chemistry, 278, (11) pp. 9309-9317. ISSN 0021-9258 (2003) [Refereed Article]

DOI: 10.1074/jbc.M300003200 [eCite] [Details]

Citations: Scopus - 62Web of Science - 59

Tweet

2002Beamish H, Kedar P, Kaneko H, Chen P, Fukao T, et al., 'Functional link between BLM defective in Bloom's syndrome and the ataxia-telangiectasia-mutated protein, ATM', Journal of Biological Chemistry, 277, (34) pp. 30515-30523. ISSN 0021-9258 (2002) [Refereed Article]

DOI: 10.1074/jbc.M203801200 [eCite] [Details]

Citations: Scopus - 89Web of Science - 87

Tweet

2001Dittmann KH, Gueven N, Mayer C, Rodemann HP, 'Characterization of the amino acids essential for the photo- and radioprotective effects of a Bowman-Birk protease inhibitor -derived nonapeptide', Protein Engineering, 14, (3) pp. 157-160. ISSN 0269-2139 (2001) [Refereed Article]

DOI: 10.1093/protein/14.3.157 [eCite] [Details]

Citations: Web of Science - 13

Tweet

2001Gueven N, Keating KE, Chen P, Fukao T, Khanna KK, et al., 'Epidermal Growth Factor Sensitizes Cells to Ionizing Radiation by Down-regulating Protein Mutated in Ataxia-Telangiectasia', Journal of Biological Chemistry, 276, (12) pp. 8884-8891. ISSN 0021-9258 (2001) [Refereed Article]

DOI: 10.1074/jbc.M006190200 [eCite] [Details]

Citations: Scopus - 41Web of Science - 37

Tweet

Chapter in Book

(1 outputs)
YearCitationAltmetrics
2016Lean QY, Gueven N, Eri RD, Peterson GM, Patel RP, 'Non-Anticoagulant Oligosaccharides of Enoxaparin Relieve Chemical-Induced Acute Colitis', Advances in Medicine and Biology, Nova Science Publishers, LV Berhardt (ed), United States, pp. 87-104. ISBN 978-1-63483-988-4 (2016) [Research Book Chapter]

[eCite] [Details]

Co-authors: Lean QY; Eri RD; Peterson GM; Patel RP

Review

(9 outputs)
YearCitationAltmetrics
2015Buyse GM, Gueven N, McDonald CM, 'Idebenone as a Novel Therapeutic Approach for Duchenne Muscular Dystrophy', European Neurological Review, 10, (2) ISSN 1758-3837 (2015) [Review Several Works]

[eCite] [Details]

2015Yin X, Guven N, Dietis N, 'Opioids in Depression: Not Quite There Yet', UK Journal of Pharmaceutical and Biosciences, 3, (1) pp. 12-17. ISSN 2347-9442 (2015) [Substantial Review]

[eCite] [Details]

Co-authors: Yin X; Dietis N

2014Gueven N, 'Optic Neurodegeneration: Time to Act', Biology and Medicine, 1, (1) pp. 1-6. ISSN 0974-8369 (2014) [Substantial Review]

DOI: 10.4172/0974-8369.S1-001 [eCite] [Details]

Tweet

2013Gueven N, Faldu D, 'Therapeutic strategies for Leber's hereditary optic neuropathy: A current update', Intractable & Rare Diseases Research., 2, (4) pp. 130-135. ISSN 2186-3644 (2013) [Substantial Review]

[eCite] [Details]

Co-authors: Faldu D

2013Guven N, Faldu D, 'Idebenone treatment in Leber's hereditary optic neuropathy: rationale and efficacy', Expert opinion on orphan drugs, 2, (4) pp. 130-135. ISSN 2167-8707 (2013) [Substantial Review]

DOI: 10.1517/21678707.2013.772894 [eCite] [Details]

Citations: Scopus - 2

Co-authors: Faldu D

Tweet

2008Lavin MF, Gueven N, Grattan-Smith P, 'Defective responses to DNA single- and double-strand breaks in spinocerebellar ataxia', DNA Repair, 7 pp. 1061-1076. ISSN 1568-7864 (2008) [Substantial Review]

DOI: 10.1016/j.dnarep.2008.03.008 [eCite] [Details]

Citations: Scopus - 13

Tweet

2007Lavin MF, Guven N, Bottle S, Gatti RA, 'Current and potential therapeutic strategies for the treatment of ataxia-telangiectasia', British Medical Bulletin, 81-82, (1) pp. 129-147. ISSN 0007-1420 (2007) [Substantial Review]

DOI: 10.1093/bmb/ldm012 [eCite] [Details]

Citations: Scopus - 80

Tweet

2005Lavin MF, Birrell G, Chen P, Kozlov S, Scott S, et al., 'ATM signaling and genomic stability in response to DNA damage', Mutation Research - D N Aging, 569, (1-2) pp. 123-32. ISSN 0921-8734 (2005) [Substantial Review]

[eCite] [Details]

2004Lavin MF, Scott S, Gueven N, Kozlov S, Peng C, et al., 'Functional consequences of sequence alterations in the ATM gene', D N A Repair, 3, (8-9) pp. 1197-205. ISSN 1568-7864 (2004) [Review Several Works]

[eCite] [Details]

Conference Publication

(1 outputs)
YearCitationAltmetrics
2003Truman J-P, Gueven N, Lavin M, Leibel S, Kolesnick R, et al., 'Transcriptional down-regulation of Ataxia-Telangiectasia Mutated protein (ATM) radiosensitizes human prostate cancer cells', INIS Collection, 17-22 August 2003, Brisbane, Australia, pp. 100. (2003) [Refereed Conference Paper]

[eCite] [Details]

Patent

(4 outputs)
YearCitationAltmetrics
2012Feurer A, Gueven N, Hoffman-Enger B, Erb M, Deppe H, et al., 'Benzoquinone Derivatives as Modulators of Mitochondrial Function' (2012) [Patent]

[eCite] [Details]

2012Feurer A, Hoffmann-Enger B, Deppe H, Soeberdt M, Gueven N, et al., 'Novel Benzoquinone Derivatives and Use Thereof as Modulators of Mitochondrial Function' (2012) [Patent]

[eCite] [Details]

2000Dittmann K, Guven N, Mayer C, Rodemann PH, 'Protection of cells in connection with treatment with chemical agents' (2000) [Patent]

[eCite] [Details]

1999Rodemann H, Dittmann K, Guven N, Mayer C, 'Peptide with radio protective effect' (1999) [Patent]

[eCite] [Details]

Grants & Funding

Assoc Prof Gueven's work is currently funded by charities, academic funding bodies and commercial entities: CIA on 4 pharmaceutical industry-related grants: 1x Department of Industry grant in 2014 (A$100k), 2x MarinovaPte research grants (~A$50k each) and 1x pilot grant with international pharmaceutical company (~A$50k). Multiple smaller grants from foundations and charities (A$10-20k per grant).

Funding Summary

Number of grants

18

Total funding

$1,564,064

Projects

Anti-inflammatory efficacy of Marinovas Fucoidan & interactions with microbiota (2016)$100,000
Description
Industry interaction to develop Marinovas fucoidan extracts for gut health
Funding
Department of Industry, Innovation and Science ($50,000); Marinova Pty Ltd ($50,000)
Scheme
Contract Research
Administered By
University of Tasmania
Research Team
Guven N; Eri RD; Ahuja KDK; Ball MJ; Ambrose M; Roddam LF; Zosky GR
Year
2016
Short chain quinones against diabetic retinopathy (2016 - 2019)$40,193
Description
We will test novel short chain quinones against idebenone and related compounds in a rat model of diabetic retinopathy.
Funding
Santhera Pharmaceuticals Holding AG ($40,193)
Scheme
Contract Research
Administered By
University of Tasmania
Research Team
Guven N; Premilovac D; Foa LC
Period
2016 - 2019
Generating and characterizing a reliable rodent model type 2 diabetes (2016)$14,673
Funding
University of Tasmania ($14,673)
Scheme
Grant-Research Enhancement (REGS)
Administered By
University of Tasmania
Research Team
Premilovac D; Foa LC; Taylor BVM; Guven N
Year
2016
Fucoidan and cell cycle regulation (2015 - 2016)$54,917
Description
This project involves industry interaction to develop Marinova's fucoidan extract against cancer.
Funding
Marinova Pty Ltd ($54,917)
Scheme
Contract Research
Administered By
University of Tasmania
Research Team
Guven N; Dietis ND; Davis E
Period
2015 - 2016
Fucoidan and stem cell mobilisation (2015)$54,095
Description
Industry interaction to test if Marinova's fucoidan extracts mobilise stem cells.
Funding
Marinova Pty Ltd ($54,095)
Scheme
Clinical Trial
Administered By
University of Tasmania
Research Team
Guven N; Eri RD; Ahuja KDK; Patel RP
Year
2015
Fucoidan and gut health (2015)$100,000
Description
This project represents industry interaction to develop Marinovas fucoidan extract for gut health.
Funding
Department of Industry and Science ($50,000)
Scheme
Grant
Administered By
University of Tasmania
Research Team
Guven N; Davis E; Eri RD; Patel RP
Year
2015
Bi-functional opioids as a novel cancer treatment (2015)$6,567
Description
The aim of our study is to assess the anticancer effect of our 10 novel opioid drugs in six different intestinal cancer cell lines and compare them with oxaliplatin and irinotecan. The particular objectives of the study are:1. To evaluate the effect of our novel drugs on intestinal cancer cell viability, growth, proliferation and ability to form colonies.2. To explore the molecular mechanisms of the anticancer activity of our novel drugs.
Funding
Cancer Council of Tasmania ($6,567)
Scheme
Grant-Cancer Research
Administered By
University of Tasmania
Research Team
Dietis ND; Liu JJ; Holloway AF; Guven N
Year
2015
Novel short-chain quinones against inherited blindness (2015)$6,900
Description
Sufficient cellular energy production is essential for normal vision, which is exemplified by Lebers Hereditary Optic Neuropathy (LHON). This disorder is a devastating disease that affects predominantly young men in their 20s to 30s. Affected individuals typically have normal vision, before in their 20s they irreversibly lose their vision. Currently, there is no treatment on the market to prevent or restore vision loss. However, several clinical trials in LHON and other mitochondrial optic neuropathy patients support a limited therapeutic benefit of short-chain quinone compounds. Based on previous in-depth experience with this class of compounds in vitro and in-vivo acquired in commercial and academic laboratories, the project proposes to discover and characterize novel quinone compounds with improved activity. This project is based on a rational medicinal-chemistry optimization program to improve the activity of known molecules and to provide a safe and cost-effective prevention and therapy option for optic neuropathy patients.
Funding
Rebecca L Cooper Medical Research Foundation ($6,900)
Scheme
Grant
Administered By
University of Tasmania
Research Team
Guven N
Year
2015
Non anticoagulant molecules of heparin for the management of ulcerative colitis (2015)$15,000
Description
This project aims to achieve the identification and evaluation of non-anticoagulant molecules of heparin that are responsible for the observed beneficial effects of heparin in patients with ulcerative colitis as well as to compare potential biomarkers in a preclinical muse model with ulcerative colitis patients.
Funding
Royal Hobart Hospital Research Foundation ($15,000)
Scheme
Grant-Clinical Research
Administered By
University of Tasmania
Research Team
Patel RP; Guven N; Eri RD; Bhatia R
Year
2015
Development of a therapeutic agent for a chemotherapy-induced neuropathy (2015)$21,739
Description
Chemotherapy-induced neuropathy (CIN) is a dose-limiting side effect of chemotherapy treatment, causing irreversible disability in 40% of cancer survivors. CIN results from the loss or damage of neurons during chemotherapy. We have compelling evidence that the protein metallothionein promotes regeneration of peripheral nerves, and examine its therapeutic use in CIN.This project will create new knowledge in the area of chemotherapy induced neuropathy, and establish the suitability of trophic agents as disease-modifying agents for chemotherapy-induced neuropathy.
Funding
Royal Hobart Hospital Research Foundation ($21,739)
Scheme
Grant-Clinical Research
Administered By
University of Tasmania
Research Team
Taylor BVM; Landowski LM; West AK; Vickers JC; Foa LC; Guven N
Year
2015
Comparison of idebenone and CoQ10 (2014)$3,830
Description
This project is a literature overview on the comparison of the two benzoquinones idebenone and CoQ10, with regards to biological and therapeutic activity.
Funding
Santhera Pharmaceuticals Holding AG ($3,830)
Scheme
Consultancy
Administered By
University of Tasmania
Research Team
Guven N
Year
2014
Fucoidan extract in the treatment of ulcerative colitis in an animal model (2013)$2,810
Description
Brown algal extracts, in particular those containing fucoidan have been shown to have potential applications in a number of health indications such as prediabetes, immunomodulation, cardiovascular disease, inflammation and gut health. With advances in technology, fucoidan extracts from brown seaweed can now be produced successfully on a commercial scale. These types of extracts are beginning to become more prevalent as ingredients in western dietary supplement markets. However, for the extracts to successfully enter this market, efficacy, safety and provenance must be proven to help gain acceptance. With this in mind, the objectives of this project include the following: to establish the efficacy of high purity fucoidan extract from Fucusvesiculosus in the treatment of ulcerative colitis in an animal model; and to compare the efficacy of the routes of administration of Fucusvesiculosus fucoidan in treating ulcerative colitis with particular reference to oral and intra-peritoneal dosages.
Funding
Marinova Pty Ltd ($2,810)
Scheme
Contract Research
Administered By
University of Tasmania
Research Team
Peterson GM; Guven N; Patel RP
Year
2013
Neuroprotective function of novel short chain-quinones (2013)$9,090
Description
Most eye disorders are associated with mitochondrial dysfunction. Based on the mitochondria-protective drug idebenone, we will synthesize novel, improved neuroprotective compounds. These compounds will be tested in a microfluidics cell culture model of mechanical stress-induced neuro-degeneration to identify new treatments strategies against retinal degeneration.
Funding
Royal Hobart Hospital Research Foundation ($9,090)
Scheme
Grant-Research
Administered By
University of Tasmania
Research Team
McCartney PJ; Guven N; Guijt RM; Smith JA
Year
2013
Protection against spontaneous and radiation-induced intestinal cancer by the novel antioxidant CTMIO (2008)$160,000
Funding
The Cancer Council, Queensland ($160,000)
Scheme
Project
Administered By
Queensland Institute of Medical Research
Research Team
Lavin MF; Gueven N
Year
2008
Use of the novel nitroxide antioxidant CTMIO in a GAA repeat mouse model of Friedreichs Ataxia (2007)$100,000
Funding
National Ataxia Foundation (NAF) / Friedreich’s Ataxia Research Alliance (FARA), USA ($100,000)
Scheme
Kyle Bryant Translational Research Award
Administered By
Queensland Institute of Medical Research
Research Team
Gueven N; Pook M
Year
2007
Senataxin, a novel protein involved in the DNA damage response (2007 - 2009)$466,500
Funding
National Health and Medical Research Council ($466,500)
Scheme
Project
Administered By
Queensland Institute of Medical Research
Research Team
Lavin MF; Gueven N; Becherel O
Period
2007 - 2009
Functional Role of Aprataxin: Mutated in Ataxia with Oculomotor Apraxia (2005 - 2007)$267,750
Funding
National Health and Medical Research Council ($267,750)
Scheme
Project
Administered By
Queensland Institute of Medical Research
Research Team
Lavin MF; Gueven N
Period
2005 - 2007
Role of ATX/hSMG1 protein in responding to DNA damage and maintaining genome stability (2004 - 2005)$140,000
Funding
Queensland Cancer Fund ($140,000)
Scheme
Project
Administered By
Queensland Institute of Medical Research
Research Team
Lavin MF; Gueven N
Period
2004 - 2005

Research Supervision

Nuri supervises a number of PhD candidates at the University of Tasmania. Recently, one of his students was invited to present her results at a prestigious Gordon Conference in Italy and another one generated the data that resulted in a patent application. He also trained numerous technical staff and actively mentors the junior colleagues within Pharmacy. He is involved in undergraduate teaching and is a regular contributor to practicals and tutorials for Pharmacy students. The quality and impact of his undergraduate lectures has been acknowledged by both the course co-ordinators and students.

Current

12

Completed

2

Current

DegreeTitleCommenced
PhDPharmaceutical Studies on Jack Jumper Ant Venom Immunotherapy Products2012
PhDThe Role of Mitochondria in the Visual Function of Zebrafish (Danio. rerio)2013
PhDIn Vivo Investigation of Behavioural Influence of Six Bifunctional Opioid Ligands2013
PhDCopper Transporter 1 as a Cellular determinant of the Sensitivity of Colorectal Cancer to Oxaliplatin Chemotherapy2013
PhDSynthesis of New Derivatives Targeting Mitochondrial Disease2013
PhDAnalgesic and Pharmacokinetic Studies of the Bifunctional Opioid UFP-5052014
PhDSecondary Metabolites from Tasmanian Plants2014
PhDNovel Napthoquinones Against Neurodegeneration2014
PhDDevelopment and Validation of Zebrafish Models for Studying Behavioral Patterns of Cognitive Functions and Affective Disorders2015
PhDTherapeutic Efficacy of Oligosaccharides of Novel Low Weight Heparin, Enoxaparin in Management of Asthma2015
PhDTargeting Wnt Signaling Pathway in the Treatment of Colorectal Cancer2016
PhDDrug-Driving in Tasmania: Acute and Chronic Effects of Quetiapine and Opioids on Driving Ability2016

Completed

DegreeTitleCompleted
PhDBioprocess Monitoring Using Sequential Injection Capillary Electrophoresis
Candidate: Ala Abdul Kareem Ahmad Alhusban
2016
PhDHeparins and Fucoidans: Future therapeutic options for ulcerative colitis
Candidate: Qi Ying Lean
2016